Real-world utilization of andexanet alfa
Real-world utilization of andexanet alfa
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
AbstractObjectiveIn 2018, the FDA approved andexanet alfa for the reversal of life-threatening hemorrhages in patients anticoagulated with apixaban or rivaroxaban. Yet, cost-effective factor Xa inhibitor reversal remains controversial. The objective of this study was to describe real world utilization of andexanet alfa. MethodsThis was a retrospect...
Alternative Titles
Full title
Real-world utilization of andexanet alfa
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2330325565
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2330325565
Other Identifiers
ISSN
0735-6757
E-ISSN
1532-8171
DOI
10.1016/j.ajem.2019.12.008
